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The human retrovirus XMRV (xenotropic murine leukemia virus-related virus) is associated with prostate
cancer, but a causal relationship has not been established. Here, we have used cultured fibroblast and
epithelial cell lines to test the hypothesis that XMRV might have direct transforming activity but found only
rare transformation events, suggestive of indirect transformation, even when the target cells expressed the
human Xpr1 cell entry receptor for XMRV. Characterization of cells from three transformed foci showed that
all were infected with and produced XMRV, and one produced a highly active transforming virus, presumably
generated by recombination between XMRV and host cell nucleic acids. Given the sequence similarity of
XMRV to mink cell focus-forming (MCF) viruses and the enhanced leukemogenic activity of the latter, we
tested XMRV for related MCF-like cytopathic activities in cultured mink cells but found none. These results
indicate that XMRV has no direct transforming activity but can activate endogenous oncogenes, resulting in
cell transformation. As part of these experiments, we show that XMRV can infect and be produced at a high
titer from human HT-1080 fibrosarcoma cells that express TRIM5 (Ref1), showing that XMRV is resistant
to TRIM5 restriction. In addition, XMRV poorly infects NIH 3T3 cells expressing human Xpr1 but relatively
efficiently infects BALB 3T3 cells expressing human Xpr1, showing that XMRV is a B-tropic virus and that its
infectivity is regulated by the Fv1 mouse locus.
The association of human prostate cancer with mutations
that impair the function of the antiviral defense protein RNase
L suggested a role for virus in prostate cancer. Indeed, analysis
of cDNA from prostate tumors by use of a DNA microarray
(Virochip) containing conserved DNA sequences from all
known virus families indicated the presence of a novel gam-
maretrovirus in 40% of prostate cancer patients having ho-
mozygous R462Q mutations in RNase L (35). Cloning and
sequencing of the virus revealed a close similarity to mouse
xenotropic retroviruses; thus, the new virus was named XMRV
(xenotropic murine leukemia virus-related virus) (35). Impor-
tantly, XMRV has been found integrated into human genomic
DNA from tumor-bearing prostatic tissue samples of 11 pa-
tients, showing that XMRV can indeed infect humans and is
not a laboratory contaminant (7, 13). Although an initial study
found XMRV only in tumor stromal cells (35), recent studies
have found XMRV in the prostate carcinoma cell line 22Rv1
(14) and in malignant epithelial cells in prostate tumors (34).
XMRV lacks a host cell-derived oncogene, but examples of
oncogenic activity in Env proteins from other retroviruses (1, 6,
16, 24) raise the possibility that the Env protein of XMRV
might also be oncogenic. Such activity could be a result of
interaction of the XMRV Env protein with the virus entry
receptor Xpr1 (7, 14), which shows similarity to a yeast protein
involved in G protein-coupled signal transduction (2), or in-
teraction with other cellular proteins that do not function as
virus entry receptors, as is the case for jaagsiekte sheep retro-
virus (JSRV) Env (interacting protein unknown) (16) and the
Env protein of spleen focus-forming virus, which interacts with
and activates the erythropoietin receptor and the receptor ty-
rosine kinase Stk (24). Detection of XMRV oncogenic activity
would strengthen the argument for a role for XMRV in pros-
tate cancer.
In addition, while XMRV shows the highest sequence sim-
ilarity to the mouse xenotropic retroviruses, it is also similar to
the mink cell focus-forming (MCF) retroviruses of mice, which
are highly leukemogenic due to their ability to multiply reinfect
cells, leading to more-frequent activation of cellular oncogenes
(36). MCF viruses were first defined by their ability to induce
foci of altered cells in mink cell layers (11). Initially, it was
unclear whether these foci were the result of cell transforma-
tion or cytopathic effects of the virus (11), but it is clear now
that these foci result from cytopathic effects related to the
ability of MCF viruses to multiply reinfect cells in what can be
a receptor-independent manner, leading to cell apoptosis (23,
36, 37). It was thus important to determine if XMRV has
similar properties and might be able to more frequently acti-
vate cellular oncogenes.
Here, we have found that while XMRV lacks direct transform-
ing activity in the fibroblast and epithelial cell lines tested and
does not induce cytopathic effects typical of multiple reinfection
by MCF viruses, it is able to induce rare transformed foci in a rat
fibroblast cell line. Interestingly, in one case, transformation led
to the production of a highly active oncogenic retrovirus.
MATERIALS AND METHODS
Cell culture and viruses. Cells were propagated in Dulbecco’s modified Ea-
gle’s medium (DMEM) with 7% fetal bovine serum (FBS), with the exception
that PG-4 cat cells (9) were grown in McCoy’s medium with 15% FBS. HTX cells
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are a pseudodiploid subclone of HT-1080 cells (ATCC CCL 121). The LAPSN
retroviral vector (22) contains the human placental alkaline phosphatase (AP)
cDNA driven by the viral long terminal repeat (LTR) promoter and the neomy-
cin phosphotransferase cDNA driven by the simian virus 40 early promoter.
LAPSN vector infection was measured by staining cells for heat-stable placental
AP 2 days after infection, as described previously (8). 10A1 amphotropic murine
leukemia virus (AM-MLV) was obtained from NIH 3T3 cells transfected with
the permuted 10A1 virus DNA clone pB6 (26) after the plasmid was cut with SalI
and the DNA was religated to generate intact 10A1 provirus circles. Prior to use,
virus-containing medium from cells was filtered through 0.45-m-pore-size sur-
factant-free cellulose acetate filters. All retrovirus infections were performed by
exposing subconfluent cells to virus in the presence of 4 g Polybrene per ml.
XMRV preparations. Several sources of XMRV were used: XMRV from
22Rv1 cells (ATCC CRL-2505) (14), XMRVLAPSN virus from HTX/LAPSN
cells infected with virus from 22Rv1 cells, XMRV from LNCaP or HTX cells
infected with virus produced from HEK 293 cells following transfection with the
XMRV-VP62 molecular clone (a kind gift from Robert Silverman) (7), and
XMRVLAPSN virus from HTX/LAPSN cells infected with virus from XMRV-
VP62-transfected 293 cells. The XMRV titers in these preparations were found
to range from 3  106 to 107 focus-forming units (FFU) per ml when measured
by SL assay. In virus preparations containing the LAPSN vector, the LAPSN
titers were found to range from 2  107 to 6  107 AP FFU per ml when
measured by using PG-4 SL cells as targets for infection.
SL assay for replication-competent retroviruses. PG-4 cells were seeded at
2 105 cells per 6-cm dish (diameter 52 mm) or 105 cells per well (diameter
35 mm) of 6-well plates. The next day, the cells were fed with fresh medium
containing 4 g Polybrene per ml and test samples were added. Foci resulting
from the rescue and spreading of the transforming virus present in the PG-4 cells
by replication-competent virus in the test sample were counted when well de-
veloped (3 to 6 days after infection). LAPSN virus in the test sample was
quantitated by staining the PG-4 cells for AP and counting AP foci immediately
after the transformed foci were counted.
RESULTS
XMRV does not directly transform 208F rat fibroblasts.
Cultured 208F rat fibroblasts (27) grow to form a flat mono-
layer that will persist without cell overgrowth for more than a
month when fed every 3 to 4 days with DMEM plus 5% FBS.
These cells exhibit foci of piled-up, rounded, dividing cells in
response to transfection or infection with a variety of onco-
genes. To test for oncogenic activity of XMRV, we exposed
208F cells to 0.25 ml of XMRVLAPSN virus made from
HTX/LAPSN cells infected with XMRV produced by 22Rv1
prostate carcinoma cells (14). The presence of the LAPSN
vector in the XMRVLAPSN virus preparation provided a
marker to easily measure virus infection rates by staining cells
for AP. Indeed, staining for AP 2 days after virus exposure
revealed that nearly 100% of the 208F cells exposed to the
virus but none of the unexposed cells expressed AP, indicating
efficient virus infection. The LAPSN vector was also found to
be produced by the XMRVLAPSN-infected 208F cells at a
titer of 2  103 AP FFU per ml of medium exposed to the
cells overnight when measured 6 days after virus exposure.
Because the LAPSN vector encodes no viral proteins, produc-
tion of the vector implies that all of the XMRV viral proteins
were expressed in the 208F cells.
Microscopic observation of the 208F cells for 20 days after
infection revealed one focus of transformed cells (Fig. 1A) in
three 6-cm-diameter dishes of cells infected with XMRV
LAPSN virus and none in three 6-cm-diameter dishes of unin-
fected cells. The focus of transformed cells appeared late after
infection (2 weeks) and consisted primarily of piled up cells that
were not very refractile, unlike foci induced by the JSRV Env
gene, for example, which appear in as little as 3 days and are
highly refractile (Fig. 1B and C). The appearance of only one
transformed focus in cells that were almost all infected indicates
that XMRV lacks direct transforming activity but may mediate
FIG. 1. Morphology of transformed foci in 208F fibroblasts. 208F and 208F/LhXpr1SN cells seeded the day before at 1  105 to 2  105 cells
per 6-cm dish were infected with XMRVLAPSN virus (produced by HTX/LAPSN cells infected with virus from 22Rv1 cells) (A, D, E), were
transfected with the pSX2Jenv plasmid by using the calcium phosphate method (B, C), or were treated with culture medium only (F). The cells
were trypsinized and replated in multiple 6-cm dishes 1 day (A, D to F) or 10 days (B, C) after treatment. Areas with (A to D) and without (E
and F) foci are shown. Cell layers were photographed at the indicated times after replating. d, days.
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low-frequency indirect transformation, perhaps by activation of
cellular oncogenes.
We repeated this experiment by using the same stock of
XMRVLAPSN virus and several related viruses, including
NZB clone 9-1 xenotropic murine leukemia virus (25) plus the
LAPSN vector, Friend MCF strain 98D virus (4), and AM-
MLV (20). The NZBLAPSN virus was made, like the
XMRVLAPSN virus, by infecting cells transduced with the
LAPSN vector with NZB virus and by harvesting the mixed
virus from these cells. The 208F cells were exposed to 0.5 ml of
each virus stock (106 infectious units) or control medium.
Microscopic observation of the infected and uninfected 208F
cells for 18 days revealed no foci of transformed cells (three
10-cm-diameter dishes for each condition). AP staining of the
cells at this time revealed that 95% of the XMRVLAPSN-
infected cells, 80% of the NZBLAPSN-infected cells, and
none of the uninfected cells expressed AP, indicating efficient
infection by these viruses. The MCF and amphotropic virus
stocks did not contain the LAPSN vector, and we did not
monitor infection, but previous results indicate that infection
by these viruses should have occurred (data not shown).
Generation of 208F rat fibroblasts expressing human Xpr1.
The finding that 208F cells are efficiently infected by the
LAPSN vector pseudotyped by XMRV shows that 208F cells
express a functional Xpr1 receptor for XMRV, but we wanted
to test whether the human Xpr1 (hXpr1) protein might be
required for transformation by XMRV. Therefore, we gener-
ated 208F cells expressing hXpr1 by exposing 208F cells to the
retroviral vector LhXpr1SN (2), produced in the absence of
replication-competent retrovirus by using PT67 retrovirus
packaging cells (18), and by growing the 208F cells in G418 to
select for the presence of the neomycin phosphotransferase
gene carried by the vector. To test for functional expression of
the hXpr1 protein, we measured XMRVLAPSN infection of
208F cells and 208F cells expressing the LhXpr1SN vector
(Table 1). The titer of the LAPSN vector was, on average,
42%  8% (standard error [SE]) higher on 208F/LhXpr1SN
cells than on 208F cells. To control for factors that affect
infection independent of receptor function, we also compared
the XMRVLAPSN titers normalized to 10A1LAPSN vec-
tor titers and found an average increase of 34%  4% (SE) on
208F/LhXpr1SN cells in comparison to the level for 208F cells.
This increase is statistically significant (P 	 0.02) and indicates
that the LhXpr1SN vector encodes a functional Xpr1 receptor
in the transduced 208F cells.
Because 208F cells are relatively susceptible to XMRV in-
fection, and the infection rate was only modestly increased by
transduction of the 208F cells with the LhXpr1SN vector, we also
tested the activity of the LhXpr1SN vector in mouse cells that are
resistant to xenotropic virus entry. The XMRVLAPSN virus did
not infect NIH 3T3 or BALB 3T3 mouse cells (	1 AP FFU per
ml), but transduction of these cells with the identical frozen
LhXpr1SN vector preparation used to make the 208F/LhXpr1SN
cells, followed by selection of the cells in G418, rendered the NIH
3T3 and BALB 3T3 cells susceptible to infection by the
XMRVLAPSN virus (titers of 90 and 2 104 AP FFU per ml,
respectively [means of results from two experiments]). The BALB
3T3/LhXpr1SN cells were 200-fold more infectible than were
the NIH 3T3/LhXpr1SN cells, indicating that XMRV is a B-
tropic retrovirus and that XMRV infection is partially restricted
in NIH 3T3 cells. These results show that the LhXpr1SN vector
encodes a functional Xpr1 protein.
XMRV does not directly transform 208F rat fibroblasts ex-
pressing human Xpr1. To test the effect of hXpr1 expression
on 208F cell transformation by XMRV, the 208F/LhXpr1SN
cells were exposed to 0.5 ml of XMRVLAPSN, NZB
LAPSN, or MCF viruses, all of which can use hXpr1 for cell
entry (2, 14), or no virus as a negative control. Microscopic
observation for over 1 month revealed four foci of transformed
cells in three 6-cm-diameter dishes of XMRVLAPSN-in-
fected cells and no foci in any of the other cultures. Figure 1
shows an example of a focus in an XMRV-infected culture
(Fig. 1D), the flat appearance of the cells in other areas of the
dish (Fig. 1E), and the flat appearance of uninfected cells (Fig.
1F). The foci produced in the 208F/LhXpr1SN cells, like the
transformed focus described above for XMRV-infected 208F
cells (Fig. 1A), were visible only long after infection (2
weeks) and were composed primarily of piled-up cells that
were not very refractile. In total, our results show that XMRV
and NZB xenotropic viruses, and likely the MCF and ampho-
tropic viruses, are unable to directly transform 208F cells even
if the cells express hXpr1, although XMRV could induce rare
foci of transformed cells. In addition, we saw no evidence of
transformation by hXpr1.
XMRV does not transform Madin Darby canine kidney
(MDCK) epithelial cells. MDCK cells exhibit prototypical ep-
ithelial cell morphology, grow in tight clusters, and remain as a
monolayer after they reach confluence. These cells have been
used to assay transformation by multiple oncogenes, including
the JSRV env gene (17), and may be more appropriate than
fibroblasts as a model for transformation of prostate
epithelial cells. We exposed subconfluent MDCK cells to
XMRVLAPSN virus or control medium and fed the cells
with DMEM plus 5% FBS every 3 to 4 days for 20 days. There
were no morphological differences between the control and
virus-exposed cultures (three 6-cm-diameter dishes each), and
no transformed foci were observed. AP staining 2 days after
virus exposure revealed that 10 to 20% of the cells exposed to
XMRVLAPSN virus and none of the uninfected cells ex-
pressed AP, showing that the cells exposed to XMRV
LAPSN virus had been infected. The LAPSN vector was also
TABLE 1. Human Xpr1 expression in 208F cells increases their
susceptibility to XMRV infectiona
Virus Expt
Titer (AP FFU/ml) of
LAPSN vector
on cells Ratio
XMRV ratio
normalized
to 10A1
ratio208F/hXpr1 208F
XMRVLAPSN 1 4.55  106 2.90  106 1.57 1.27
2 2.54  106 1.90  106 1.34 1.34
3 4.16  106 3.09  106 1.35 1.42
10A1LAPSN 1 1.68  107 1.35  107 1.24
2 7.40  106 7.40  106 1.00
3 1.23  107 1.30  107 0.95
a Cells were seeded at 5  104 cells per well in 6-well plates, were infected the
next day with appropriate dilutions of XMRVLAPSN virus harvested from
HTX/LAPSNXMRV cells (XMRV was from 22Rv1 cells) or 10A1LAPSN
virus from Mus dunni/LAPSN10A1 cells (21), and were stained for AP 2 days
after infection. Results are from three independent experiments.
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found to be produced by the infected MDCK cells at a titer of
2  104 AP FFU per ml of medium exposed to the cells
overnight when measured 6 days after virus exposure, showing
that the XMRV viral proteins (including Env) were expressed
in the XMRVLAPSN-exposed MDCK cells. Thus, XMRV
can infect and replicate in but does not transform MDCK cells.
Plasmids expressing XMRV or XMRV Env do not transform
208F cells with or without coexpression of hXpr1. We consid-
ered the possibility that the promoter in XMRV might not
express XMRV Env at high enough levels to elicit cell trans-
formation. To address this issue, we cloned the XMRV env
coding region from the XMRV-VP62 infectious molecular
clone (7) (GenBank accession no. EF185282) into the pSX2
expression vector in place of the existing 10A1 amphotropic
env coding region to make pSX2Xenv. In this plasmid, XMRV
Env expression is driven by the strong Moloney murine leuke-
mia virus LTR promoter, and we have shown that insertion of
the JSRV env coding region into the same site in the pSX2
vector yields a plasmid (pSX2Jenv) that can transform 208F
cells in just a few days (28). We performed two separate trans-
fections by using either calcium phosphate (3) or Transit-LT1
transfection reagent (Mirus Bio), and by using either 208F or
208F/LhXpr1SN cells as targets for transfection, to test the
transforming activity of pSX2Xenv; a mixture of equal
amounts of pSX2Xenv and the pLhXpr1SN plasmid; and
pXMRV-VP62. Control transfections included the pSX2 plas-
mid, encoding the nontransforming 10A1 amphotropic Env
protein, and the pSX2Jenv plasmid, encoding the highly trans-
forming JSRV Env protein, as a positive control. We also
included a small amount of the pLAPSN vector plasmid (5% of
the test plasmids by mass) to allow estimation of transfection
efficiency by AP staining. No transformed foci were observed
for pSX2 or for the plasmids expressing XMRV Env or the
complete XMRV cDNA clone, while many foci were observed
for the pSX2Jenv plasmid, encoding JSRV Env (Table 2). AP
staining of the cell layers revealed similar transfection rates in
each experiment for the pSX2, pSX2Xenv, and pSX2Xenv-
plus-pLhXpr1SN plasmids. There was a significant increase in
transfection rate for the pSX2Jenv plasmid, suggesting that
transformation by the pSX2Jenv plasmid enhances stable
transfection. There was a more dramatic increase in AP foci
in cells transfected with pXMRV-VP62, most likely reflecting
a spread of the LAPSN vector due to XMRV replication and
a concomitant mobilization of the LAPSN vector.
To prove that the pSX2 and pXMRV-VP62 plasmids ex-
pressed functional Env protein, we transfected these plasmids
into NIH 3T3 cells that express Moloney MLV Gag-Pol pro-
teins (19) and were transduced with the LAPSN vector (LGPS/
LAPSN cells). Table 3 shows that the pSX2Xenv, pXMRV-
VP62, pSX2, and pSX2Jenv plasmids have similar abilities to
rescue the LAPSN vector from LGPS/LAPSN cells but that the
negative-control plasmid pUC19 had no activity. In summary,
despite encoding functional Env protein, none of the XMRV
expression plasmids were able to transform 208F cells or 208F
cells expressing hXpr1.
XMRV lacks the cytopathic activity of MCF viruses. The
cytopathic effects of MCF viruses in cultured mink Mv1Lu cells
(ATCC CCL-64) correlate with their ability to multiply rein-
fect (superinfect) the cells, thereby inducing apoptosis (23, 37).
Multiple reinfections also result in more-frequent oncogene
activation in hematolymphoid cells of mice infected with MCF
viruses, resulting in frequent induction of leukemias. Given the
similarity of XMRV to xenotropic and MCF retroviruses, we
tested whether XMRV could also induce cytopathic effects in
mink cells as an indicator of an ability to multiply reinfect the
cells. Mink cells were seeded at 1  105 to 2  105 per 6-cm
dish and, on the next day, were infected with over 106 infec-
tious units of XMRVLAPSN, Friend MCF strain 98D (4), or
NZB xenotropic (25) virus. The cells were then grown, and
every time they became confluent, they were trypsinized and
split 1:10. In two independent experiments, cytotoxicity (a re-
duction in the number of attached cells and the appearance of
floating cells) was first observed in the MCF-infected cells at
days 3 and 5 and in the NZB-infected cells at days 11 and 12,
and no toxicity was observed in the XMRV-infected cells or in
the uninfected cells passaged in parallel for 40 days after in-
fection. AP staining of the XMRVLAPSN-infected cells at
TABLE 2. XMRV expression plasmids do not transform 208F or
208F/LhXpr1SN cellsa
Transfection
method Test plasmid(s)
No. of foci in cell line
Transformed AP
208F 208F/LhXpr1SN 208F
208F/
LhXpr1SN
CaPO4 pSX2 0 0 18 22
pSX2Xenv 0 0 20 20
pSX2Xenv,
pLhXpr1SN
0 0 18 21
pXMRV-VP62 0 0 2,000 1,600
pSX2Jenv 720 980 164 172
Transit-LT1 pSX2 0 0 190 340
pSX2Xenv 0 0 420 640
pSX2Xenv,
pLhXpr1SN
0 0 310 350
pXMRV-VP62 0 ND 1,600 ND
pSX2Jenv 3,800 3,600 810 960
a Transformed foci were counted 17 (CaPO4) or 18 (Transit-LT1) days after
transfection, and AP foci were counted 17 (CaPO4) or 19 (Transit-LT1) days
after transfection. Numbers represent the total numbers of transformed and
AP foci induced by 10 g test plasmids plus 0.5 g pLAPSN plasmid DNA,
used for each CaPO4 transfection (3) or by 5 g test plasmids plus 0.25 g
pLAPSN plasmid DNA, used for each Transit-LT1 transfection (Mirus Bio).
Plates that exhibited no transformed foci remained negative for at least 24
(CaPO4) and 30 (Transit-LT1) days after transfection. ND, no data.
TABLE 3. Production of functional Env proteins by
XMRV plasmidsa
Transfected plasmid LAPSN vector titer(no. of AP FFU/ml)
pUC19 ................................................................................ 	2
pSX2Xenv ..........................................................................5.5  103
pXMRV-VP62...................................................................6.6  103
pSX2 ...................................................................................1.3  104
pSX2Jenv ...........................................................................4.2  103
a LGPS/LAPSN cells (NIH 3T3 thymidine kinase-negative cells expressing
Moloney MLV Gag-Pol proteins 
19 and containing the LAPSN vector) were
transfected with the indicated plasmids by calcium phosphate coprecipitation (5).
One day after transfection, the cells were fed, and 2 days after transfection, the
culture medium was harvested and filtered through 0.45-m-pore-size filters to
remove cells and debris, and the medium samples were assayed for LAPSN
vector titer by infection of HTX cells. Results are means for two independent
experiments.
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12 days (experiment 1) or 36 days (experiment 2) after infec-
tion revealed 50 to 70% AP cells, showing that the cells had
been efficiently infected. After the first toxicity was observed in
the MCF and NZB virus-infected cells, these populations
nearly completely died over a period of a week, although ul-
timately, clones of cells that were resistant to the cytotoxicity of
each virus grew out. We found that the cells that became
resistant to MCF virus cytotoxicity were producing the MCF
virus and thus were still infected (data not shown), but we have
not determined the nature of the acquired resistance to cyto-
toxicity. These results document the novel finding that NZB
xenotropic virus is cytotoxic in mink cells, although it is less
potent than the MCF virus, while XMRV shows no cytotoxicity
in mink cells. On the basis of previously described correlations
between cytotoxicity and reinfection (23, 36, 37), we conclude
that XMRV is less able to multiply reinfect the mink cells than
are the MCF and NZB retroviruses.
XMRV does not transform mink cells. Mv1Lu lung epithe-
lial cells grow to form a flat contact-inhibited monolayer and
have been used to assay for transformation by mammalian sar-
coma viruses (12). To test whether XMRV could induce trans-
formed foci in the mink cells, we allowed XMRVLAPSN-in-
fected mink cells to reach confluence and continued to feed the
cells with DMEM plus 5% FBS every 3 to 4 days for over a
month. In two experiments, we did not detect any foci indica-
tive of transformation in XMRV-infected cultures.
Further characterization of rare 208F cell transformation
by XMRV. We considered the possibility that rare transforma-
tion of 208F cells by XMRV originally obtained from 22Rv1
cells was due to contamination with a rare transforming virus,
so we generated a clonal stock of XMRV from the VP62
plasmid clone of XMRV by transfection of 293 cells, infected
HTX/LAPSN cells with this virus, and assayed 1 ml of virus
from the HTX/LAPSNXMRV VP62 cells for transformation
of 208F cells. One focus of transformation was detected in a
10-cm dish, similar to the results described above, by using
XMRV originally from 22Rv1 cells, indicating that a clonal
stock of XMRV can also induce rare transformed foci in 208F
cells. We also tested XMRV directly from 22Rv1 cells for
transforming activity. The use of 2 ml of this virus in an assay
involving 8 10-cm dishes of 208F cells revealed five trans-
formed foci, showing that neither the growth of XMRV in
HTX cells nor the presence of the LAPSN vector was required
for rare transformation events to occur.
To characterize the properties of transformed foci that arose
after XMRVLAPSN virus infection, we isolated cells from
three foci (Fig. 2A, B, and C). Cloning rings were first used to
isolate cells from the foci along with nearby nontransformed
208F cells, and then the cells were plated at a limiting dilution
to enable isolation of clonal transformed cell lines. Cells from
all three foci retained a stable transformed phenotype after
cloning (Fig. 2D and E and data not shown), including cells
from the very weakly transformed focus 1 (Fig. 2A and D).
Cells from foci 1 and 2 showed a lack of contact inhibition,
resulting in piled-up cell growth, while focus 3 showed a highly
transformed phenotype (Fig. 2D and E and data not shown).
Cells from all foci produced replication-competent virus by an
SL assay (Table 4), indicating infection by and production
of XMRV. Cells from all foci stained positive for AP (not
shown) and produced virus encoding AP (Table 4), indicating
FIG. 2. Morphology of transformed foci of 208F cells and purification of the transformed cells. Panels A to C show transformed foci at 27 days
(focus 1) or 15 days (foci 2 and 3) after plating of XMRV-infected 208F cells (see Table 4 for infection details). Panel D shows the mixed
population of transformed and nontransformed cells 1 week after plating of cells from focus 1 that were obtained by using a cloning ring. Panel
E shows two colonies of cells produced by plating low numbers of mixed cells from focus 3. The left colony is clearly transformed and resembles
the cells in the original focus (C), while the right colony appears to be a colony of untransformed parental 208F cells. Panel F shows a focus of
transformed cells (lower-left part of picture) induced by infection of 208F cells with virus from focus 3 cells.
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infection by and production of the LAPSN vector as well.
Assay of medium from these cells for the presence of virus that
could transform 208F cells (Table 4) showed that cells from
foci 1 and 2 did not produce transforming virus but that focus
3 cells produced a relatively high titer of a virus that rapidly
transformed 208F cells (Fig. 2F), with morphological changes
in the 208F cells being visible within about 4 days.
DISCUSSION
Given the potential role of XMRV in prostate cancer and
the ability of some retroviruses to directly transform cells, it
was important to test whether XMRV is capable of direct
transformation. However, we found no transformation by
XMRV in canine kidney (MDCK) and mink lung epithelial
cells and found only rare transformation events in 208F rat
fibroblasts. Although 208F cells express a functional Xpr1 cell
entry receptor for XMRV, we also tested whether expression
of human Xpr1 in these cells might lead to increased transfor-
mation but found no increase. The few foci that we did observe
in 208F fibroblasts with or without hXpr1 arose long after
XMRV infection (2 weeks) and typically had a piled-up
appearance (Fig. 1A and D), unlike the transformed foci in-
duced by oncogenes such as JSRV env (Fig. 1B and C) and the
fos oncogene (28), which arise in a few days and are composed
of rounded separated cells that can readily detach from the cell
layer. These results indicate that XMRV has no direct trans-
forming activity but may be able to activate cellular oncogenes
at low rates, leading to transformation.
In contrast to rare transformation of 208F fibroblasts by
XMRV, we did not see any transformation of MDCK and
mink lung epithelial cells by XMRV. These epithelial cell types
were less efficiently infected by XMRV than were 208F rat
fibroblasts; therefore, the rates of virus integration and onco-
gene activation might have been too low for detection of trans-
formation. Alternatively, the 208F cells may simply be more
sensitive to transformation. It is also surprising that we did not
see focus formation by NZB, MCF, or amphotropic viruses in
208F cells. While this may be due to intrinsic differences be-
tween XMRV and the other viruses, an alternative explanation
is that differences in infection rates are responsible for this
result. In none of these cases have we tried to detect transfor-
mation by greatly increasing the amount of virus and number
of target cells used.
During testing for hXpr1 activity as a receptor for XMRV,
we found that XMRVLAPSN virus could efficiently infect
BALB 3T3 cells expressing hXpr1 but was 200-fold less able to
infect NIH 3T3 cells expressing hXpr1, characteristics of B-
tropic murine retroviruses. N and B tropism is governed by the
mouse Fv1 locus and depends on sequences in the viral capsid
protein. Consistent with the conclusion that XMRV is B tropic,
the XMRV capsid residues at all positions shown to affect N
and B tropism (residues 92, 105, 109, 110, 114, and 117) match
those of the typical B-tropic murine retrovirus WNB5 MLV
(15). B-tropic murine retroviruses are also typically resistant to
Ref1 (TRIM5) restriction in human cells. HT-1080 cells ex-
press high levels of TRIM5 (15), and the XMRVLAPSN
virus can efficiently infect and replicate in HTX cells (a sub-
clone of HT-1080 cells), showing that XMRV is also resistant
to TRIM5 restriction.
XMRV shows no cytotoxicity in mink cells, unlike MCF
virus, which caused dramatic death starting at 3 to 5 days after
infection, and NZB xenotropic virus, which caused dramatic
death starting at 11 to 12 days after infection. Cell death
caused by MCF viruses has been shown to result from the
ability of MCF to multiply reinfect cells, indicating that XMRV
is not able to reinfect cells to the same extent. However, it is
true that multiple XMRV proviruses can be found in some
prostate carcinoma cells (14), so oncogene activation by
XMRV is not precluded.
Transformed 208F cell foci were not observed in control
uninfected cells or in cells infected with NZB, MCF, or am-
photropic retroviruses, so transformed foci produced by
XMRV do not appear to be artifactual. Several XMRV prep-
arations were used in these experiments, including virus from
22Rv1 cells, which may be heterogeneous due to the multiple
integrated copies of XMRV in these cells, and virus containing
the LAPSN vector, which could contribute to transformation.
However, transformed foci were also observed with the use of
presumably homogenous virus made from the XMRV-VP62
plasmid clone and with the use of virus from 22Rv1 cells that
does not contain the LAPSN vector. In addition, production of
transformed foci was not dependent on the cell type used to
grow XMRV; foci were observed with the use of XMRV from
22Rv1 cells and from HTX cells infected with virus from 293
cells transfected with the XMRV-VP62 plasmid clone. To-
gether, these results indicate that XMRV itself is responsible
for rare focus formation in the 208F cells.
The rare transformed foci induced by XMRV and
XMRVLAPSN virus preparations that we have observed are
likely the result of virus integration near and activation of
oncogenes in the infected cells. Such events are very well doc-
umented for animals infected with many types of retroviruses
(33) and have been documented for humans receiving retrovi-
ral vectors to treat genetic disease (10). Such events might also
contribute to prostate cancer in humans but would require
multiple integration events resulting from active virus replica-
tion in prostate cells. Interestingly, cells from one of the trans-
formed foci that we studied (focus 3) are producing a highly
active transforming virus in addition to the XMRV and
LAPSN viruses used to infect these cells (Table 4). Many such
transforming viruses have been observed and characterized for
TABLE 4. Characteristics of and virus production by cells derived
from transformed 208F focia
208F
focus
Presence of
hXpr1
Infecting
XMRV
virus
Virus production level (FFU/ml)
SL foci AP foci Transformingvirus
1 Yes 22Rv1 4  103 2  104 	1
2 No VP62 600 104 	1
3 No 22Rv1 2.5  104 9  105 3  104
a Medium was harvested 12 to 24 h after feeding of confluent layers of cells
obtained from transformed foci of 208F cells (foci 2 and 3) or 208F/LhXpr1SN
cells (focus 1) infected with the indicated viruses. The medium was assayed for
replication-competent virus by an SL assay. After the SL foci were counted
microscopically, the cells were stained for AP, and AP foci were counted in the
same dishes. The presence of transforming virus in medium harvested from cells
obtained from the transformed foci was measured by exposing 208F cells to 1 ml
of virus and by checking for transformed foci for 1 month after infection. For
focus 3, transformed foci were visible within 5 days of infection and were counted
at 10 days after infection with diluted virus.
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animals (33) and have also been generated in a few cases in
cultured cells (29–32). We are currently cloning and will se-
quence the acutely transforming virus to understand its gene-
sis, specifically, whether it acquired an oncogene from the 208F
rat cells in which the transformed focus appeared.
In summary, the lack of direct transforming activity and an
inability to readily reinfect cells, leading to more-frequent on-
cogene activation, argue against two models for XMRV onco-
genesis in the prostate. However, our results indicate that
XMRV, like other retroviruses, might still induce cancer by
low-frequency insertional activation of oncogenes or by gener-
ation of highly active transforming viruses.
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